Sorafenib exerts anti-glioma activity in vitro and in vivo. - Wikidata - awgldk - TriplyDB

Sorafenib exerts anti-glioma activity in vitro and in vivo.

Sorafenib exerts anti-glioma activity in vitro and in vivo.

http://www.wikidata.org/entity/Q35414966

about

Novel delivery strategies for glioblastoma The role of STAT3 in autophagy JSI-124 suppresses invasion and angiogenesis of glioblastoma cells in vitro Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects RFX1-dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells.The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.Role of autophagy in angiogenesis in aortic endothelial cells.Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway.Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures.Bevacizumab for glioblastoma: current indications, surgical implications, and future directions Combining molecular targeted agents with radiation therapy for malignant gliomas Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.An update in the use of antibodies to treat glioblastoma multiforme.Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.Olmesartan potentiates the anti-angiogenic effect of sorafenib in mice bearing Ehrlich's ascites carcinoma: role of angiotensin (1-7)Angiogenesis and invasion in glioma.Antiangiogenic therapies in glioblastoma multiforme.Antiangiogenic therapy in the management of brain tumors: a clinical overview.Autophagy and cancer: taking the 'toxic' out of cytotoxics.Antiangiogenic therapy for high-grade gliomas: current concepts and limitations.New molecules and old drugs as emerging approaches to selectively target human glioblastoma cancer stem cells.Chemotherapeutic xCT inhibitors sorafenib and erastin unraveled with the synaptic optogenetic function analysis tool Inhibition of Autophagy by Chloroquine Enhances the Antitumor Efficacy of Sorafenib in Glioblastoma.Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner Sorafenib and lithium chloride combination treatment shows promising synergistic effects in human glioblastoma multiforme cells in vitro but midkine is not implicated.Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas.HDAC inhibitor DWP0016 activates p53 transcription and acetylation to inhibit cell growth in U251 glioblastoma cells.Molecular mechanisms of sorafenib action in liver cancer cells.Sorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines.Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma.Human mesenchymal stromal cells as cellular drug-delivery vectors for glioblastoma therapy: a good deal?SCO-spondin oligopeptide inhibits angiogenesis in glioblastoma.

P2860

Q27006099-48DC737D-B213-4490-B701-D26268D6D0A1 Q28084959-93B88E7F-B16E-405B-B4B6-205EB232550F Q28544728-4447C9B0-88C1-44CC-9823-2B7864FF05B1 Q33404027-AFE20A76-CA97-4355-B022-863ADD159591 Q33933312-E6ACF111-E1AA-47D9-A221-0BEA2515D8BD Q34104089-FB0F8896-ACAE-433D-8DDF-411FB8A982F1 Q34458602-A76C4F2A-E945-420D-8E7D-4EB51635F6AD Q35895542-39798331-F3FF-492D-BBAA-D95A56BE5E28 Q36351752-5A840B3B-27F0-452C-B14C-0C4E7C64B518 Q36654402-0AB3739A-A9F6-489F-A778-EA5F590C5576 Q36822207-53DD2DA2-88CC-47EB-9AEB-50E7D57C4A94 Q37099594-14733365-0842-4C9B-A23C-466E9EE8377E Q37308322-11A6378E-98B2-4BCA-93B1-4B078A785928 Q37329927-AB211189-CD3B-42F2-ABD3-22B708BC463E Q37407066-32978F7E-6E86-4E98-8CDE-32BA4460E43A Q37505197-284EC5C1-274F-4371-9E80-69F63E13DDB9 Q37827399-1F64CFC9-CAB6-43DF-A408-108CD6CDFC37 Q38010802-28F12BA0-1C20-456D-BCF6-415B1B78FE4B Q38028766-73EA75BC-85A6-49A4-B8CB-35A7B3DAF9B9 Q38104448-5DDD2F8E-B7EE-470D-A121-904B28675B47 Q38157034-548545EF-BB14-432B-A73B-FFEBD4CB41DC Q38187997-58FC58BE-8D75-4CC3-B95D-24634459DEE4 Q38611037-D14FA659-846D-4F62-A7FF-B7D35B3F6738 Q38786782-341E1251-EC91-475E-8061-E0D22B5CA6F3 Q38841816-0E1DB080-F234-46DD-8954-208E568D2D2B Q39025471-5C5E11DA-CA19-4B02-9515-BF3AA6204488 Q39040289-037CF7CB-FA99-4C06-BF60-77F36714E551 Q39214706-756D5D64-8405-4DF2-B205-40BB94BFE9A4 Q39313526-1B5C4229-4CF7-4068-94F2-1F3DFCD420A2 Q39472878-5DABD527-DB1D-486F-9AAF-30722AA285F3 Q39493324-B32CE66B-8D96-4450-B9CF-BFAF055A07A6 Q42368133-29742CCE-9428-47BB-94CA-6F015F312A9F Q47106590-26DAFB55-43FE-4D9C-8A03-1983950DACB4

P2860

Sorafenib exerts anti-glioma activity in vitro and in vivo.

http://www.wikidata.org/entity/Q35414966

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Sorafenib exerts anti-glioma activity in vitro and in vivo.

@ast

Sorafenib exerts anti-glioma activity in vitro and in vivo.

@en

type

label

Sorafenib exerts anti-glioma activity in vitro and in vivo.

@ast

Sorafenib exerts anti-glioma activity in vitro and in vivo.

@en

prefLabel

Sorafenib exerts anti-glioma activity in vitro and in vivo.

@ast

Sorafenib exerts anti-glioma activity in vitro and in vivo.

@en

P1433

Q35414966-C4D3E7B1-0F31-4CFF-82F6-ABFC54106656

P1476

Q35414966-12F91F94-A39B-47B8-B16D-A4C2F6A4AF76

P2093

Q35414966-0B5FE2C5-A4DC-4CC9-BD30-A8EEF452E56B

Q35414966-0BEBC598-1E49-4793-BB63-E5CB307F4157

Q35414966-30B99082-4298-457F-925C-A06DB2922DD8

Q35414966-81AC6918-1F07-4AE6-9A3A-D175BF9275AB

Q35414966-FCBDE73A-637C-4B07-B220-5023B0B0BF0B

P2860

Q35414966-03DBEF32-EB80-4D19-8266-70680403A3A3

Q35414966-041256DD-A030-4843-A55D-A914950E5276

Q35414966-1E1B1CDA-6D62-42D8-9836-1045F32154B8

Q35414966-315C4640-E974-4CB7-9E17-3F68439B2064

Q35414966-31774456-4311-4B0A-879E-FD147DCFBF95

Q35414966-3B224155-9321-493A-8946-41E234639B4B

Q35414966-3BFC08D2-6E28-4F7E-9703-A4EFE0A36645

Q35414966-3EC34205-0BDD-494E-9C0F-227D2E27E729

Q35414966-429C9056-683B-4BC8-B9C0-296B988B1D82

Q35414966-469F9C2D-D608-4B17-BDE7-B754B868D5F1

P304

Q35414966-25D221BA-A5F1-43B4-B1B6-F7C45C2A86B0

P31

Q35414966-FA7B990B-F83C-4C82-B721-1DEAC81527C5

P356

Q35414966-26D9D1DA-54E3-4961-B69C-7730C94CEBEB

P407

Q35414966-AD6EBAEF-F7A2-478F-BECB-F18356112811

P433

Q35414966-21E86537-0F44-42D8-BD93-759063C821A1

P478

Q35414966-6B44A5DC-1688-4399-BAB9-A2CDC60AA111

P577

Q35414966-A895A6CA-038F-4743-A017-9EF6BF1EE65B

P5875

Q35414966-E20426D0-C460-4A71-ABCD-6A8198777BE7

P698

Q35414966-7DA3706A-B27E-4582-A0E7-7FFF5E59F7BA

P932

Q35414966-FC6819B3-D3A3-4CCF-AA3D-8D3A557B26C3

P356

J.NEULET.2010.05.009

P1433

Neuroscience Letters

P1476

Sorafenib exerts anti-glioma activity in vitro and in vivo.

@en

P2093

Alonzo H Ross

http://www.w3.org/2001/XMLSchema#string

Candace A Gilbert

http://www.w3.org/2001/XMLSchema#string

Christopher M Raskett

http://www.w3.org/2001/XMLSchema#string

Dario C Altieri

http://www.w3.org/2001/XMLSchema#string

Markus D Siegelin

http://www.w3.org/2001/XMLSchema#string

P2860

Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression

Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.

Stat3 activation is required for the growth of U87 cell-derived tumours in mice

Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.

Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway

Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis.

New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy.

P304

165-170

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NEULET.2010.05.009

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

478

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44600108

http://www.w3.org/2001/XMLSchema#string

P698

20470863

http://www.w3.org/2001/XMLSchema#string

P932

3198851

http://www.w3.org/2001/XMLSchema#string